what's the dosing for tirzepatide Zepbound (Tirzepatide) Dosage Guide Weight Loss Tirzepatide $125/mo Compounded (vs $1,069

Dosing is individualized, but a typical protocol titrates from a starting dose up to a target dose over 2 to 4 weeks, injected 5 days on and 2 days off, in defined cycles with scheduled breaks between them

I do think the high folate w/ the (absent?) B12 is suspicious

PlexusDx recommends coordinating with your primary care provider or endocrinologist to review thyroid labs quarterly during the first year of GLP-1 therapy

At a 50% penetration rate, a 68-week course of Mounjaro would (in this ideal, nave assumption) bring the obesity rate to the lowest level its been since 1981

Supernatants collected were kept at 20C, then insulin was measured using the protocol below, and BCA assay (Thermo Scientific, 23227) was performed to normalize insulin secretion to total protein content

Codon optimized GshF GCCGGATCTAGCTAGTTAATTAAGccaccatgACCCTTAATCAGCTTCTCCAGAAGTTGGAGGCGACT TCCCCCATTCTCCAGGCGAACTTCGGGATAGAAAGGGAGTCATTGAGGGTTGACCGCCAGGGTCA GCTGGTCCACACACCGCACCCCTCATGTCTGGGAGCCCGCAGTTTTCATCCTTACATACAAACCG ACTTTTGTGAATTCCAAATGGAACTGATTACACCAGTAGCCAAAAGTACGACGGAGGCCCGACGCT TTCTTGGCGCGATAACTGATGTAGCAGGACGAAGCATTGCAACTGACGAGGTGCTGTGGCCATTG AGTATGCCACCACGACTTAAAGCCGAGGAAATTCAAGTAGCGCAACTCGAGAACGACTTCGAAAG ACATTATCGGAACTACTTGGCAGAGAAGTACGGCACCAAATTGCAGGCGATTAGTGGAATTCATTA CAATATGGAACTTGGGAAGGACTTGGTTGAGGCGCTTTTTCAAGAGTCAGATCAGACTGACATGAT CGCATTTAAAAACGCTCTGTATCTCAAGCTCGCCCAGAACTATTTGAGGTATCGGTGGGTCATTAC TTACCTGTTTGGAGCAAGTCCCATTGCAGAACAAGGATTCTTTGACCAAGAAGTGCCGGAGCCTAT GCGCTCTTTCCGCAACTCCGACCACGGCTACGTTAACAAGGAAGAGATACAGGTAAGCTTTGTAT CCCTTGAAGACTATGTCTCCGCGATCGAGACCTACATCGAGCAGGGTGACCTTATAGCCGAGAAA GAGTTTTACTCAGCCGTGCGCTTTAGAGGACAAAAAGTCAATCGCTCCTTCCTTGATAAGGGTATA ACTTATCTGGAGTTCAGAAACTTTGACTTGAACCCATTTGAGAGAATAGGCATCAGTCAAACCACTA TGGATACCGTTCACTTGCTCATACTGGCCTTTCTCTGGTTGGATAGTCCGGAAAACGTGGACCAG GCCCTTGCCCAGGGACACGCGCTTAACGAGAAAATAGCCCTCTCCCATCCATTGGAGCCCCTCCC TTCAGAGGCCAAGACACAGGACATCGTGACCGCACTCGACCAGCTCGTACAGCACTTCGGATTGG GAGATTACCACCAGGATCTCGTGAAACAAGTGAAAGCGGCGTTTGCTGATCCGAATCAAACCCTG TCAGCTCAACTTCTTCCTTATATTAAGGACAAGTCACTCGCAGAATTCGCTCTCAATAAGGCACTCG CATATCATGACTATGACTGGACCGCTCACTACGCCCTTAAAGGTTACGAAGAAATGGAGCTCAGTA CGCAGATGCTGCTCTTTGATGCTATCCAGAAAGGAATACACTTCGAGATACTCGATGAGCAAGATC AGTTCTTGAAGCTGTGGCATCAAGATCACGTAGAATATGTTAAAAACGGTAATATGACCAGCAAGG ATAACTATGTAGTACCTCTCGCAATGGCCAACAAGACTGTTACTAAGAAAATTCTTGCTGACGCTG GGTTCCCTGTTCCGTCCGGGGACGAATTTACTAGCTTGGAGGAGGGACTGGCCTACTACCCGCTT ATTAAAGATAAGCAAATTGTAGTAAAGCCAAAGAGCACGAATTTCGGCTTGGGTATCAGCATCTTC CAAGAACCCGCCAGTCTCGACAATTATCAAAAAGCATTGGAAATAGCATTTGCGGAGGACACTAGT GTGCTCGTCGAAGAATTCATTCCAGGCACGGAATACCGATTCTTCATTTTGGACGGACGCTGTGA GGCAGTCCTTTTGAGGGTAGCTGCCAATGTAATAGGGGACGGGAAACACACAATCAGAGAGTTGG TAGCGCAGAAAAACGCAAATCCCCTGCGCGGTAGGGATCATAGATCACCCTTGGAAATCATAGAG CTTGGGGACATAGAGCAACTCATGCTGGCACAGCAGGGTTACACTCCAGATGACATCCTGCCAGA GGGTAAGAAAGTGAATTTGAGGCGGAACAGCAATATTAGTACTGGGGGAGACTCCATAGACGTCA CAGAAACAATGGATAGCTCTTATCAAGAACTTGCAGCAGCGATGGCTACCAGTATGGGGGCATGG GCCTGTGGAGTTGATCTGATTATACCCGACGAAACGCAGATTGCCACAAAGGAAAATCCACATTGC ACGTGTATTGAACTTAACTTCAACCCCTCCATGTACATGCATACATACTGCGCTGAGGGGCCGGG GCAGGCAATTACAACCAAAATACTCGACAAACTCTTCCCGGAGATCGTGGCCGGACAAACTGGAG GAAGCGGAGGAAGCGGAGGAAGCGATTACAAGGATGACGATGACAAGTAAGCTACGTAAATTCC GCCC Mito-GSHf GCCGGATCTAGCTAGTTAATTAAGccaccATGCTCGCTACAAGGGTCTTTAGCCTCGTCGGAAAGAG AGCTATCAGCACCTCCGTCTGCGTGAGAGCTCATatggcgccctacagcctactggtgactcggctgcagaaagctctg ggtgtgcggcagtaccatgtggcctcagtcctgtgcGATTACAAGGATGACGATGACAAGGGAGGAAGCGGAGGAA GCGGAGGAAGCACCCTTAATCAGCTTCTCCAGAAGTTGGAGGCGACTTCCCCCATTCTCCAGGCG AACTTCGGGATAGAAAGGGAGTCATTGAGGGTTGACCGCCAGGGTCAGCTGGTCCACACACCGC ACCCCTCATGTCTGGGAGCCCGCAGTTTTCATCCTTACATACAAACCGACTTTTGTGAATTCCAAAT GGAACTGATTACACCAGTAGCCAAAAGTACGACGGAGGCCCGACGCTTTCTTGGCGCGATAACTG ATGTAGCAGGACGAAGCATTGCAACTGACGAGGTGCTGTGGCCATTGAGTATGCCACCACGACTT AAAGCCGAGGAAATTCAAGTAGCGCAACTCGAGAACGACTTCGAAAGACATTATCGGAACTACTTG GCAGAGAAGTACGGCACCAAATTGCAGGCGATTAGTGGAATTCATTACAATATGGAACTTGGGAA GGACTTGGTTGAGGCGCTTTTTCAAGAGTCAGATCAGACTGACATGATCGCATTTAAAAACGCTCT GTATCTCAAGCTCGCCCAGAACTATTTGAGGTATCGGTGGGTCATTACTTACCTGTTTGGAGCAAG TCCCATTGCAGAACAAGGATTCTTTGACCAAGAAGTGCCGGAGCCTATGCGCTCTTTCCGCAACTC CGACCACGGCTACGTTAACAAGGAAGAGATACAGGTAAGCTTTGTATCCCTTGAAGACTATGTCTC CGCGATCGAGACCTACATCGAGCAGGGTGACCTTATAGCCGAGAAAGAGTTTTACTCAGCCGTGC GCTTTAGAGGACAAAAAGTCAATCGCTCCTTCCTTGATAAGGGTATAACTTATCTGGAGTTCAGAA ACTTTGACTTGAACCCATTTGAGAGAATAGGCATCAGTCAAACCACTATGGATACCGTTCACTTGC TCATACTGGCCTTTCTCTGGTTGGATAGTCCGGAAAACGTGGACCAGGCCCTTGCCCAGGGACAC GCGCTTAACGAGAAAATAGCCCTCTCCCATCCATTGGAGCCCCTCCCTTCAGAGGCCAAGACACA GGACATCGTGACCGCACTCGACCAGCTCGTACAGCACTTCGGATTGGGAGATTACCACCAGGATC TCGTGAAACAAGTGAAAGCGGCGTTTGCTGATCCGAATCAAACCCTGTCAGCTCAACTTCTTCCTT ATATTAAGGACAAGTCACTCGCAGAATTCGCTCTCAATAAGGCACTCGCATATCATGACTATGACT GGACCGCTCACTACGCCCTTAAAGGTTACGAAGAAATGGAGCTCAGTACGCAGATGCTGCTCTTT GATGCTATCCAGAAAGGAATACACTTCGAGATACTCGATGAGCAAGATCAGTTCTTGAAGCTGTGG CATCAAGATCACGTAGAATATGTTAAAAACGGTAATATGACCAGCAAGGATAACTATGTAGTACCTC TCGCAATGGCCAACAAGACTGTTACTAAGAAAATTCTTGCTGACGCTGGGTTCCCTGTTCCGTCCG GGGACGAATTTACTAGCTTGGAGGAGGGACTGGCCTACTACCCGCTTATTAAAGATAAGCAAATTG TAGTAAAGCCAAAGAGCACGAATTTCGGCTTGGGTATCAGCATCTTCCAAGAACCCGCCAGTCTC GACAATTATCAAAAAGCATTGGAAATAGCATTTGCGGAGGACACTAGTGTGCTCGTCGAAGAATTC ATTCCAGGCACGGAATACCGATTCTTCATTTTGGACGGACGCTGTGAGGCAGTCCTTTTGAGGGT AGCTGCCAATGTAATAGGGGACGGGAAACACACAATCAGAGAGTTGGTAGCGCAGAAAAACGCAA ATCCCCTGCGCGGTAGGGATCATAGATCACCCTTGGAAATCATAGAGCTTGGGGACATAGAGCAA CTCATGCTGGCACAGCAGGGTTACACTCCAGATGACATCCTGCCAGAGGGTAAGAAAGTGAATTT GAGGCGGAACAGCAATATTAGTACTGGGGGAGACTCCATAGACGTCACAGAAACAATGGATAGCT CTTATCAAGAACTTGCAGCAGCGATGGCTACCAGTATGGGGGCATGGGCCTGTGGAGTTGATCTG ATTATACCCGACGAAACGCAGATTGCCACAAAGGAAAATCCACATTGCACGTGTATTGAACTTAAC TTCAACCCCTCCATGTACATGCATACATACTGCGCTGAGGGGCCGGGGCAGGCAATTACAACCAA AATACTCGACAAACTCTTCCCGGAGATCGTGGCCGGACAAACTTAAGCTACGTAAATTCCGCCC Human codon-optimized Cyto-GshF was custom synthesized by IDT and directly assembled into pMXS-puro linearized with BamHI and NotI with a Gibson reaction